{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:24:34Z","timestamp":1793467474237,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jlb.2026.100481","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:51:18Z","timestamp":1784130678000},"page":"100481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-2024","authenticated-orcid":false,"given":"Hillary S.","family":"Andrews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevine","family":"Zariffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Goren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine K.","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abde","family":"Abukhdeir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Dajee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Ensor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin R.","family":"Espenschied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fabrizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minakshi","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilafruz","family":"Juraeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kr\u00e4emer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German G.","family":"Leparc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Levi-D\u2019Ancona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minetta","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Merino Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernat","family":"Navarro-Serer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Pestano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Solovieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Wojciekowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Hoering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff D.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlb.2026.100481_bib1","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/1078-0432.CCR-24-3612","article-title":"ctDNA clearance as an early indicator of improved clinical outcomes in advanced NSCLC treated with TKI: findings from an aggregate analysis of eight clinical trials","volume":"31","author":"Andrews","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100481_bib2","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/1078-0432.CCR-24-1883","article-title":"Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group","volume":"30","author":"Wyatt","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100481_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012454","article-title":"Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and\/or chemotherapy","volume":"13","author":"Andrews","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jlb.2026.100481_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35917","article-title":"Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C\u2010mutated advanced non\u2010small cell lung cancer","volume":"131","author":"Passiglia","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.jlb.2026.100481_bib5","article-title":"Real-world validity of tissue-agnostic circulating tumor DNA response monitoring in lung cancers treated with chemotherapy, immunotherapy, or targeted agents","volume":"6","author":"Chiang","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jlb.2026.100481_bib6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer","volume":"79","author":"Anagnostou","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jlb.2026.100481_bib7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2025.1646","article-title":"Early ctDNA and survival in metastatic colorectal cancer treated with immune checkpoint inhibitors: a secondary analysis of the SAMCO-PRODIGE 54 randomized clinical trial","volume":"11","author":"Ta\u00efeb","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jlb.2026.100481_bib8","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-22-2998","article-title":"Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer","volume":"29","author":"Tolmeijer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100481_bib9","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41388-024-02986-6","article-title":"Fulvestrant and everolimus efficacy after CDK4\/6 inhibitor: a prospective study with circulating tumor DNA analysis","volume":"43","author":"Vasseur","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.jlb.2026.100481_bib10","unstructured":"Use of circulating tumor deoxyribonucleic acid for early-stage solid tumor drug development; guidance for industry; availability | FDA. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-guidance. Accessed May 20, 2026."},{"key":"10.1016\/j.jlb.2026.100481_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/oncolo\/oyac006","article-title":"Surrogacy beyond prognosis: the importance of \u201cTrial-Level\u201d surrogacy","volume":"27","author":"Buyse","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jlb.2026.100481_bib12","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaoncol.2020.1847","article-title":"What constitutes a valid surrogate end point in cancer clinical trials?","volume":"6","author":"Shyr","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jlb.2026.100481_bib13","article-title":"Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"6","author":"Vega","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jlb.2026.100481_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","article-title":"Landmark analysis: a primer","volume":"26","author":"Morgan","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.jlb.2026.100481_bib15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jlb.2026.100481_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"key":"10.1016\/j.jlb.2026.100481_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jval.2025.01.005","article-title":"A comparison of the performance of 6 surrogacy models, including weighted linear regression, meta-regression, and bivariate meta-analysis","volume":"28","author":"Vickers","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.jlb.2026.100481_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz002","article-title":"A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses","volume":"3","author":"Xie","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.jlb.2026.100481_bib19","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/s41416-020-0805-y","article-title":"Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review","volume":"122","author":"Belin","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jlb.2026.100481_bib20","unstructured":"April 12, 2024 meeting of the oncologic drugs advisory committee meeting announcement - 04\/12\/2024 | FDA. Available at: https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/april-12-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04122024. Accessed May 20, 2026."}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:31:29Z","timestamp":1789014689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426000275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":20,"alternative-id":["S2950195426000275"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100481","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100481"}}